Stuartj Connolly News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Finding seen in patients who had taken factor Xa inhibitors within 15 hours before having acute intracerebral hemorrhage.

For patients who had taken factor Xa inhibitors within 15 hours before having an acute intracerebral hemorrhage, andexanet alfa, which reverses the effects of factor Xa inhibitors, results in better control of hematoma expansion than usual care, according to a study published in the New England Journal of Medicine.

Dr Connolly highlights the cautious patient selection and the significance of reducing hematoma expansion for improved outcomes in cases of intracerebral hemorrhage (ICH) associated with the use of a reversal agent for factor Xa inhibitors.

The FDA has approved the first-ever IV iron replacement therapy to improve exercise capacity in adults with heart failure. The IV ferric carboxymaltose injection (Injectafer; Daiichi Sankyo Inc./American Regent) was approved for patients with New York Heart Association class II/III heart failure, which is defined as a slight or marked limitation of physical activity due to fatigue, palpitation

AstraZeneca announced the ANNEXA phase IV trial assessing the safety and efficacy of andexanet alfa stopped early after achieving prespecified criteria on hemostatic efficacy vs. usual care, according to a press release. Andexanet alfa (Andexxa) is approved for patients prescribed oral factor Xa inhibitor treatment, including apixaban (Eliquis, Bristol-Myers Squibb/Pfizer) and rivaroxaban